Windrose Consulting Group are pleased welcome two new starters, Joana Lama and Kristina Funk into the London office.

Windrose are thrilled to announce two key promotions in our London office. Georgina Powell has been promoted to from Senior Analyst to Consultant and Kate Hogan from Senior Consultant to Engagement Manager.

Mark Kohler promoted to Principal and William Noumba Um to Senior Analyst at Windrose Consulting Group.

We are delighted to welcome Mattia Belloni as a Senior Consultant at Windrose.

On the 9th March Windrose ran a 1-day workshop for the masters students on the Cambridge University MPhil in Therapeutic Sciences course. The content included ‘Why it’s important to get your P&MA right’, delved into stakeholder decision analysis, the various payer systems & market archetypes, how to optimise the global strategy and communicate value.

We are pleased to announce that Agatha Cimbalova and Anjalina Mitra have been promoted to Senior Analysts. This promotion is a recognition of Agatha and Anjie’s dedication, hard work, and great progression that has been observed over their time working at Windrose.

Congratulations!

Windrose Consulting Group are pleased to continue the New Year with two new Consultants joining our growing team. Muna Ali and Stacey McDonald

Windrose Consulting Group are pleased bring in the New Year with two new Analysts on our team and a promotion within the team.

Emerging Markets are not only influential in their own regions but represent a significant proportion of the world’s population and trade. They also represent a growing share of global healthcare spending. As such they offer an attractive growth prospect for the pharmaceutical industry.

Windrose Consulting Group are pleased to welcome three new Analysts to our team.

Windrose Consulting Group are pleased to announce the September promotions for our team.

Today on World Heart Day, Windrose would like to recognize all of the innovators, healthcare providers, and family caregivers who are striving to make the world a better place for those with cardiovascular diseases (CVD).

At Windrose, we have been celebrating over a year since having acquired Parioforma, a leader in value, access and price assessments in non-traditional markets. The acquisition has strengthened Windrose’s expertise in emerging markets, which has been a significant driver of growth in recent years.

Potential ripple effects for gene therapy access

Bluebird bio, one of the world’s earliest innovators in the gene therapy space, recently announced that they will move away from launching and operating in Europe as a company, driven primarily by misalignment around the value and prices of their rare disease portfolio.

Established in 1992, the Authorization for Temporary Use program in France (ATU) is among one of the oldest and most open early access programs in Europe.[1] It allows patients with rare or serious diseases access to drugs which are currently unauthorized in that indication. Although a complex process, it appeals to manufacturers, with recent funding for ATUs growing to over €1 billion a year.[2]

At Windrose, we are celebrating a year since having acquired Parioforma, a leader in value, access and price assessments in non-traditional markets. The acquisition has strengthened Windrose’s expertise in emerging markets, which has been a significant driver of growth in recent years.

In April 2019, Japan introduced its first formal health technology assessment (HTA), driven by a cost-effectiveness analysis (CEA). The CEA was introduced to adjust the price of already reimbursed products, with the overarching aim of reducing expenditure and increasing efficiency within the healthcare system. The Ministry of Health, Labour and Welfare (MHLW) recently published the first price adjustments for several listed agents, including a 4.7% reduction for Novartis’ Kymriah, and a 0.5% reduction for GlaxoSmithKline’s Trelegy.[1-4] Here we look at what the new CEA entails, how it impacts already reimbursed products, and what the road to access may look like for new drugs in the future.

We are excited to announce the promotion of Kate Hogan to Senior Consultant at Windrose Consulting Group.

Kate has shown great leadership skills, as well as impressive management of large and very high-profile projects.

We are thrilled to see Kate’s progression, which has been instrumental in our continued growth.

We are pleased to announce the opening of our new office in Lucerne, Switzerland.

Our team at Windrose have been reflecting upon the importance of donating blood; we understand that regular blood donations are needed all over the world, to ensure individuals and communities have access to safe and quality-assured blood and blood products.